Valley National Advisers Inc Exact Sciences Corp Transaction History

Valley National Advisers Inc

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 19, 2024	SELL	$56.27 - $73.77 $7,033 - $9,221	-125 Reduced 20.73%	478 $33,000
Q4 2023 Jan 25, 2024	SELL	$59.06 - $75.72 $10,040 - $12,872	-170 Reduced 21.99%	603 $44,000
Q3 2023 Nov 13, 2023	BUY	$65.94 - $99.04 $11,605 - $17,431	176 Added 29.48%	773 $53,000
Q2 2023 Jul 31, 2023	SELL	$62.68 - $95.05 $2,507 - $3,802	-40 Reduced 6.28%	597 $57,000
Q1 2023 Apr 26, 2023	BUY	$47.19 - $70.77 $17,129 - $25,689	363 Added 132.48%	637 $42,000
Q4 2022 Jan 12, 2023	BUY	$30.35 - $53.15 $4,643 - $8,131	153 Added 126.45%	274 $18,000
Q3 2022 Nov 08, 2022	BUY	$31.97 - $49.37 $991 - $1,530	31 Added 34.44%	121 $4,000
Q2 2022 Jul 15, 2022	BUY	$35.61 - $76.23 $249 - $533	7 Added 8.43%	90 $4,000
Q1 2022 May 06, 2022	BUY	$57.56 - $82.54 $2,244 - $3,219	39 Added 88.64%	83 $6,000
Q3 2021 Nov 10, 2021	BUY	$90.24 - $124.05 $721 - $992	8 Added 22.22%	44 $4,000
Q2 2021 Aug 02, 2021	BUY	$93.66 - $139.27 $187 - $278	2 Added 5.88%	36 $4,000
Q1 2021 May 07, 2021	BUY	$116.57 - $155.01 $3,963 - $5,270	34 New	34 $4,000

673

162M

2.58M

2.19M

Ticker EXAS
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 176,960,000
Market Cap $10.2B
Description
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...

Get notified when there are updates to the investment portfolio of Valley National Advisers Inc, based on Form 13F filings with the SEC.

Stay updated on Valley National Advisers Inc with notifications on news.